Antibodies that target the crosstalk between immune and cancer cells by inhibiting programmed death 1 (PD-1, pembrolizumab and durvalumab) or programmed death-ligand 1 (PD-L1, atezolizumab) have shown promising results as second-line treatments in phase II studies with response rates of about 30%.